- Home
- SISI vs UBX Comparison
SISI vs UBX Comparison
Compare SISI & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- UBX
- Stock Information
- Founded
- SISI 1997
- UBX 2009
- Country
- SISI China
- UBX United States
- Employees
- SISI N/A
- UBX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- UBX Health Care
- Exchange
- SISI Nasdaq
- UBX Nasdaq
- Market Cap
- SISI 14.9M
- UBX 13.9M
- IPO Year
- SISI 2016
- UBX 2018
- Fundamental
- Price
- SISI $0.21
- UBX $0.78
- Analyst Decision
- SISI
- UBX Strong Buy
- Analyst Count
- SISI 0
- UBX 3
- Target Price
- SISI N/A
- UBX $4.67
- AVG Volume (30 Days)
- SISI 5.5M
- UBX 521.0K
- Earning Date
- SISI 05-15-2025
- UBX 08-05-2025
- Dividend Yield
- SISI N/A
- UBX N/A
- EPS Growth
- SISI N/A
- UBX N/A
- EPS
- SISI N/A
- UBX N/A
- Revenue
- SISI $9,601,324.00
- UBX N/A
- Revenue This Year
- SISI N/A
- UBX N/A
- Revenue Next Year
- SISI N/A
- UBX N/A
- P/E Ratio
- SISI N/A
- UBX N/A
- Revenue Growth
- SISI 1133.26
- UBX N/A
- 52 Week Low
- SISI $0.18
- UBX $0.66
- 52 Week High
- SISI $117.65
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- SISI 29.00
- UBX 48.12
- Support Level
- SISI $0.18
- UBX $0.67
- Resistance Level
- SISI $0.34
- UBX $0.83
- Average True Range (ATR)
- SISI 0.05
- UBX 0.09
- MACD
- SISI -0.01
- UBX 0.01
- Stochastic Oscillator
- SISI 11.25
- UBX 24.67
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.